Sildenafil for Benign Prostatic Hyperplasia

Guideline-Based First-Line Therapy

The American Urological Association recommends alpha-blockers (alfuzosin, doxazosin, silodosin, tamsulosin, or terazosin) as first-line treatment for bothersome, moderate to severe Lower Urinary Tract Symptoms (LUTS)/Benign Prostatic Hyperplasia (BPH), providing 4-7 point International Prostate Symptom Score (IPSS) improvement versus 2-4 points with placebo 1, 2
The American Urological Association suggests 5-alpha-reductase inhibitors (finasteride or dutasteride) for symptom improvement in patients with prostatic enlargement (prostate volume >30cc, Prostate-Specific Antigen (PSA) >1.5ng/mL, or palpable enlargement on Digital Rectal Examination (DRE)) 1, 2
Combination therapy with an alpha-blocker plus 5-alpha-reductase inhibitor is strongly recommended to prevent progression of LUTS/BPH and reduce risks of urinary retention and future prostate-related surgery, according to the American Urological Association 1, 3

Sildenafil achieved a -3.15 IPSS improvement (95% Confidence Interval (CI): -5.29 to -1.01) with an absolute effect of -6.55 points, ranking 3.70 among treatments, as shown in the network meta-analysis 1
The American Urological Association guideline's formal treatment algorithm and recommendations do not include sildenafil as standard therapy for BPH, indicating it is not considered a first-line treatment 1, 2
The 2013 American Urological Association guideline on LUTS in older men does not mention Phosphodiesterase Type 5 (PDE5) inhibitors, such as sildenafil, as a treatment option, focusing exclusively on alpha-blockers and 5-alpha-reductase inhibitors 4

The American Urological Association recommends starting with an alpha-blocker, such as tamsulosin 0.4 mg daily, due to its efficacy and lower cardiovascular effects 2, 5
For patients with prostatic enlargement (>30cc) or PSA >1.5 ng/mL, the American Urological Association suggests adding a 5-alpha-reductase inhibitor (finasteride 5 mg or dutasteride 0.5 mg daily) for disease modification and prevention of progression 1, 3

The American Urological Association recommends cardiovascular screening before prescribing any PDE5 inhibitor, ensuring the patient is not taking nitrates and assessing cardiovascular status 1, 5
Alpha-blockers carry a risk of intraoperative floppy iris syndrome during cataract surgery, and the American Urological Association suggests informing ophthalmologists and considering delaying alpha-blocker initiation until after planned cataract surgery 1, 5

The American Urological Association advises against using sildenafil as monotherapy for BPH, as it is not a guideline-supported treatment, and recommends starting with alpha-blockers or 5-alpha-reductase inhibitors as indicated 1, 2
The American Urological Association suggests not prescribing 5-alpha-reductase inhibitors without prostatic enlargement, as they are ineffective in men without enlarged prostates (>30cc) and expose patients to unnecessary sexual side effects 1, 6
The American Urological Association recommends adjusting PSA interpretation when using 5-alpha-reductase inhibitors, as they reduce PSA by approximately 50% after 1 year, and doubling the measured value for accurate prostate cancer screening 3, 5
The American Urological Association advises against assuming BPH treatment manages hypertension, as alpha-blocker therapy for BPH should not be considered optimal management of concomitant hypertension, which requires separate cardiovascular management 5